GSK reports £8.89 billion in third-quarter revenue.
Pontos principais
- GSK reported third-quarter revenue of £8.89 billion, exceeding consensus estimates due to a 15% increase in specialty medicine sales.
- Total operating profit dropped 16% to £2.13 billion following a £328 million restructuring charge, though core earnings per share beat forecasts.
- The company reaffirmed its full-year guidance, stating it expects core operating profit growth between 7% and 9% driven by stable demand.
GSK (NYSE:GSK) reported third-quarter revenue of £8.89 billion, exceeding market expectations due to increased specialty medicine sales.
The 5% constant exchange rate increase topped the £8.84 billion consensus estimate, offsetting a 2% drop in the vaccine portfolio.
Total operating profit fell 16% to £2.13 billion after the company recorded a £328 million internal restructuring charge.
The specialty medicines segment generated £3.9 billion, supported by a 23% revenue increase for oncology products and a 10% HIV increase.
General medicines revenue remained stable at £2.4 billion, aided by an 8% sales increase for the company's Trelegy product.
GSK stated that it expects full-year turnover to grow by 3% to 5% and maintained its 17 pence quarterly dividend.
_1417563_640x360_2503007299812-640x360.webp&w=3840&q=75)
